Skip to content
PubMed This is a summary of 35 peer-reviewed journal articles Updated
Neurology

Mitochondrial membrane protein-associated neurodegeneration (MPAN): A Patient Guide

At a Glance

MPAN is a rare genetic disorder linked to C19orf12 changes that progressively affects the nervous system, often causing movement and vision problems. Diagnosis uses several evaluations, and coordinated supportive care can help maintain function and quality of life even without a cure.

Mitochondrial membrane protein-associated neurodegeneration (MPAN) is a rare genetic condition that affects the way the nervous system functions over time. It belongs to a group of disorders known as Neurodegeneration with Brain Iron Accumulation (NBIA), which are characterized by the atypical buildup of iron in specific regions of the brain that control movement [1]. This iron accumulation is the result of changes in the C19orf12 gene, which normally helps maintain the health and energy production of brain cells. Researchers think that when this gene does not function correctly, it disrupts cellular processes, leading to a slow but progressive impact on physical and, sometimes, cognitive abilities [2].

What This Guide Does and Does Not Tell You

  • A diagnosis is not an exact timeline: The progression of MPAN varies widely. No guide can predict the exact course or timeline for you or your child.
  • Supportive care works: Even without a disease-modifying therapy, proactive interventions can significantly improve quality of life and manage symptoms.
  • This guide is not a substitute for medical advice: Always consult your care team for individualized advice.

The journey with MPAN typically involves changes in movement and vision that develop gradually. Most individuals first notice challenges with walking or balance, often accompanied by muscle stiffness or involuntary movements. Vision is also commonly affected through a process called optic atrophy, where the nerve connecting the eye to the brain thins over time [3]. Because these symptoms can overlap with other conditions, confirming the diagnosis involves pulling together multiple pieces. Clinicians use the clinical examination, molecular testing, brain MRI, and detailed eye examinations together to see the full picture [4]. An early MRI can be normal, and not every affected person develops optic atrophy, so no single test finding is definitively required.

While there is currently no cure for MPAN, a diagnosis provides a vital roadmap for proactive care. Management is focused on addressing symptoms as they arise through a multidisciplinary approach, bringing together specialists in neurology, physical therapy, vision, and speech [5]. Early and consistent supportive therapies—such as physical therapy to maintain mobility and speech therapy to aid communication—are the cornerstones of care. These interventions are designed to preserve independence and ensure the best possible quality of life at every stage [6].

Living with MPAN is a long-term journey that often unfolds over many years or even decades. While the progressive nature of the disorder brings new challenges, the pace varies. By coordinating with a dedicated care team and connecting with the global community of researchers and families, you can navigate this diagnosis with the support and resources needed to prioritize comfort, function, and emotional well-being [7].

Common questions in this guide

What is mitochondrial membrane protein-associated neurodegeneration (MPAN)?
MPAN is a rare genetic disorder that gradually affects the nervous system. Changes in the C19orf12 gene are linked to abnormal iron buildup in certain brain regions, and symptoms often involve movement and vision.
What symptoms might MPAN cause?
MPAN can cause difficulty walking or keeping balance, muscle stiffness, and involuntary movements. Vision may worsen because of optic atrophy, and some people also develop cognitive changes; the pattern and severity vary.
How is MPAN diagnosed if an MRI is normal?
Doctors combine a clinical examination with molecular testing for C19orf12 changes, brain MRI, and a detailed eye examination. An early MRI can be normal, and optic atrophy is not required, so diagnosis does not depend on one test result.
Is there a cure or disease-modifying treatment for MPAN?
There is currently no cure or disease-modifying treatment for MPAN. Care focuses on symptoms and may include a coordinated team with neurology, physical therapy, vision care, and speech therapy to support movement, communication, comfort, and independence.
How quickly does MPAN progress?
MPAN is progressive, but its pace and effects vary widely from person to person. Changes may unfold over many years or decades, and a diagnosis cannot predict an exact timeline for an individual.
Which specialists can help someone living with MPAN?
A multidisciplinary team may include a neurologist, physical therapist, vision specialist, and speech therapist. The team can adjust supportive care as symptoms change and help protect mobility, communication, comfort, and quality of life.
Where can families find information and support after an MPAN diagnosis?
Your care team can help connect you with patient advocacy groups, research registries, and communities of families affected by NBIA. These resources can provide practical and emotional support and may help families stay informed about research.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are the first steps we should take to build our multidisciplinary care team?
  2. 2.Which specialists in our area have experience with NBIA or rare neurogenetic conditions?
  3. 3.How can we connect with patient advocacy groups or registries to stay informed about new research?
  4. 4.What can we do right now to support our family's emotional and psychological well-being?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (7)
  1. 1

    Clinical and genetic spectrum of an orphan disease MPAN: a series with new variants and a novel phenotype.

    Akçakaya NH, Haryanyan G, Mercan S, et al.

    Neurologia i neurochirurgia polska 2019; (53(6)):476-483 doi:10.5603/PJNNS.a2019.0062.

    PMID: 31804703
  2. 2

    C19orf12 ablation causes ferroptosis in mitochondrial membrane protein-associated with neurodegeneration.

    Shao C, Zhu J, Ma X, et al.

    Free radical biology & medicine 2022; (182()):23-33 doi:10.1016/j.freeradbiomed.2022.02.006.

    PMID: 35182730
  3. 3

    Retinal and optic nerve abnormalities in neurodegeneration associated with mutations in C19orf12 (MPAN).

    Langwinska-Wosko E, Skowronska M, Kmiec T, Czlonkowska A

    Journal of the neurological sciences 2016; (370()):237-240 doi:10.1016/j.jns.2016.09.046.

    PMID: 27772766
  4. 4

    The p.Thr11Met mutation in c19orf12 is frequent among adult Turkish patients with MPAN.

    Olgiati S, Doğu O, Tufekcioglu Z, et al.

    Parkinsonism & related disorders 2017; (39()):64-70 doi:10.1016/j.parkreldis.2017.03.012.

    PMID: 28347615
  5. 5

    Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders.

    Iankova V, Karin I, Klopstock T, Schneider SA

    Frontiers in neurology 2021; (12()):629414 doi:10.3389/fneur.2021.629414.

    PMID: 33935938
  6. 6

    Rehabilitation for Mitochondrial Membrane Protein-Related Neurodegeneration: A Case Study.

    Özçelep ÖF, Turhan A, Fi Dan S, Kandemir S

    Cureus 2023; (15(12)):e50540 doi:10.7759/cureus.50540.

    PMID: 38222195
  7. 7

    Phenotype and natural history of mitochondrial membrane protein-associated neurodegeneration.

    Iankova V, Sparber P, Rohani M, et al.

    Brain : a journal of neurology 2024; (147(4)):1389-1398 doi:10.1093/brain/awad357.

    PMID: 37831662

This MPAN guide is for informational purposes only and does not replace individualized medical advice. A neurologist and multidisciplinary care team can help interpret the diagnosis and plan supportive care for you or your child.

Get notified when new evidence is published on Mitochondrial membrane protein-associated neurodegeneration.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.